hrp0082p2-d1-420 | Growth Hormone | ESPE2014
Rasmussen Michael Hojby
, Janukonyte Jurgita
, Klose Marianne
, Marina Djordje
, Tanvig Mette
, Nielsen Lene
, Hoybye Charlotte
, Andersen Marianne
, Feldt-Rasmussen Ulla
, Christiansen Jens
Background: Recombinant human GH (rhGH) is normally administered as a daily s.c. injection. NNC0195-0092 is a reversible albumin-binding GH derivative developed with the aim of reducing clearance and thereby extending the exposure. It has previously been demonstrated that NNC0195-0092 is well tolerated in healthy subjects with the potential for once weekly administration.Objective and hypotheses: In this trial NNC0195-0092 was administrated subcutaneousl...